guest column

Houston has all the ingredients to thrive as a manufacturing hub, says expert

Friday, October 1, is Manufacturing Day Houston at East End Maker Hub. Image courtesy of EEEMH

Manufacturing is critical to building the economy on both local and national levels.

According to Deloitte and The Manufacturing Institute, 4.6 million U.S. manufacturing jobs will be needed by 2030. The National Association of Manufacturing estimates that each $1 spent in manufacturing adds $2.79 to the economy and each $1 earned in direct manufacturing labor income yields $3.14 in labor income elsewhere. Failing to fill these jobs could cost the U.S. $1 trillion and thwart economic growth.

Manufacturing is a win-win for Houston. With Houston's manufacturing sectors tied to the overall U.S. economy, the Greater Houston area has the opportunity to thrive as a manufacturing powerhouse by returning manufacturing to the U.S.

"Houston is an amazing city with a wide variety of entrepreneurs, inventors and industry specialties. To support these firms, we need tens of thousands of skilled employees in a plethora of manufacturing jobs. On the product side, they include Space, Medical Devices, Robotics, Additive Manufacturing, BioEngineering, and next generation energy devices. From the process side - refined products, chemicals, beverages and plastics," said Michael Holthouse, CEO and founder of Holthouse Foundation For Kids.

In an effort to increase awareness of these advanced manufacturing careers, TXRX East End Maker Hub is hosting Manufacturing Day Houston on Friday, October 1. The event is attracting hundreds of middle- and high-school youth along with their teachers from the Greater Houston area.

EEMH is opening its doors to allow students the opportunity to engage in hands-on experiences, demonstrations, and interact with subject matter experts to learn the latest technologies in Process Manufacturing, Product Manufacturing, Bioengineering, Virtual Reality, Robotics, 3D printing and more. The keynote speaker, Jim "Mattress Mack" McIngvale of Gallery Furniture, will open the event.

Manufacturing Day Houston is a local effort to join National Manufacturing Day and Creators Wanted, both industry initiatives supported by the National Association of Manufacturers and the Manufacturing Institute. Manufacturing Day Houston has been created to reshape the perception of the advanced manufacturing industry and help today's youth understand how they can match their talents with in-demand product and process manufacturing careers that average $87,185 annually.

While attractive, many of these skilled manufacturing jobs go unfilled due to misinterpretations about the industry and educational opportunities. Houston's community colleges and technical programs offer affordable training for these opportunities, which can be completed in two years or less.

------

Michelle Wicmandy serves as a marketing consultant for Imagina Communications.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted